The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
Evangelos Terpos, MD, PhD from the University of Athens, Athens, Greece, discusses the outcomes of a clinical trial (NCT00330759) evaluating the effectiveness of denosumab compared to zoledronic acid in the treatment of bone metastases in subjects with advanced cancer and multiple myeloma (MM). Here, he explains that the three major focus points, namely safety, progression-free survival and prolongation of skeletal events were better for denosumab than for zoledronic acid and notes that the results are promising, but require further investigation. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
